PineTree Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
41
- Latest Deal Type
-
2ndary - Private
- Investors
-
21
PineTree Therapeutics General Information
Description
Developer of a biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases. The company's technology utilizes tumor-associated essential receptor-targeting antibody and virus-targeting recombinant agent platforms for infectious disease technology, enabling medical professionals to develop an anticancer drug for solid cancer patients.
Contact Information
Website
www.pinetreetx.comCorporate Office
- West Cambridge Scientific Park
- 767C Concord Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- West Cambridge Scientific Park
- 767C Concord Avenue
- Cambridge, MA 02138
- United States
PineTree Therapeutics Timeline
PineTree Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 4. Later Stage VC (Series B) | 22-Aug-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series 3) | 30-Jul-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series 2) | 07-Jun-2022 | $23.5M | $33.5M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series 1) | 01-Nov-2021 | $10M | $10M | Completed | Generating Revenue |
PineTree Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series 3 | ||||||||
| Series 2 | 2,210,785 | $0.000010 | 6% | $7 | $7 | 1x | $7 | 7.41% |
| Series 1 | 2,000,000 | $0.000010 | 6% | $5 | $5 | 1x | $5 | 6.7% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PineTree Therapeutics Comparisons
Industry
Financing
Details
PineTree Therapeutics Competitors (2)
One of PineTree Therapeutics’s 2 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
PineTree Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PineTree Therapeutics Patents
PineTree Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231613-A1 | Fab antibodies to human c-met and uses thereof | Pending | 28-Apr-2025 | ||
| WO-2026231616-A1 | Vhh antibodies to fibroblast growth factor receptor 2 (fgfr2) and uses thereof | Pending | 28-Apr-2025 | ||
| JP-2026527729-A | Non-receptor tyrosine kinase composition for targeted lysosomal degradation and method of use thereof | Pending | 28-Jul-2023 | ||
| AU-2024315751-A1 | Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof | Pending | 28-Jul-2023 | ||
| EP-4754135-A1 | Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof | Pending | 28-Jul-2023 | C07K16/2863 |
PineTree Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PineTree Therapeutics Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| Korea Investment Partners | Venture Capital | Minority | ||
| Moneyball Ventures | Venture Capital | Minority | ||
| SJG Partners | Corporate Venture Capital | Minority | ||
| SV Investment | Venture Capital | Minority |
PineTree Therapeutics FAQs
-
When was PineTree Therapeutics founded?
PineTree Therapeutics was founded in 2019.
-
Where is PineTree Therapeutics headquartered?
PineTree Therapeutics is headquartered in Cambridge, MA.
-
What is the size of PineTree Therapeutics?
PineTree Therapeutics has 41 total employees.
-
What industry is PineTree Therapeutics in?
PineTree Therapeutics’s primary industry is Drug Discovery.
-
Is PineTree Therapeutics a private or public company?
PineTree Therapeutics is a Private company.
-
What is PineTree Therapeutics’s current revenue?
The current revenue for PineTree Therapeutics is .
-
How much funding has PineTree Therapeutics raised over time?
PineTree Therapeutics has raised $97.5M.
-
Who are PineTree Therapeutics’s investors?
AstraZeneca, Korea Investment Partners, Moneyball Ventures, SJG Partners, and SV Investment are 5 of 21 investors who have invested in PineTree Therapeutics.
-
Who are PineTree Therapeutics’s competitors?
Kite Pharma and Genetix Biotherapeutics are competitors of PineTree Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
